Alan D.T. Barrett

Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus.

Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype.

Arilvax (PowderJect).

Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein.

The epidemiology of yellow fever in Africa.

Molecular characterization of a hamster viscerotropic strain of yellow fever virus.

Origin and evolution of Japanese encephalitis virus in southeast Asia.

Limited evolution of West Nile virus has occurred during its southwesterly spread in the United States.

Natural and nosocomial infection in a patient with West Nile encephalitis and extrapyramidal movement disorders.

Crystallization and preliminary X-ray diffraction analysis of Langat virus envelope protein domain III.

Analysis of the complete genome of the tick-borne flavivirus Omsk hemorrhagic fever virus.

Comparative phylogenies of yellow fever isolates from Peru and Brazil.

Genetic variation among temporally and geographically distinct West Nile virus isolates, United States, 2001, 2002.

West Nile virus in Mexico: evidence of widespread circulation since July 2002.

Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection.

Molecular determinants of antigenicity of two subtypes of the tick-borne flavivirus Omsk haemorrhagic fever virus.

Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection.

Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus.

1H, 13C and 15N resonance assignments for domain III of the West Nile virus envelope protein.

Solution structure and structural dynamics of envelope protein domain III of mosquito- and tick-borne flaviviruses.

Current status of the Arilvax; yellow fever vaccine.

Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.

Genetic relationships and evolution of genotypes of yellow fever virus and other members of the yellow fever virus group within the Flavivirus genus based on the 3' noncoding region.

West Nile virus: where are we now?

Use of recombinant E protein domain III-based enzyme-linked immunosorbent assays for differentiation of tick-borne encephalitis serocomplex flaviviruses from mosquito-borne flaviviruses.

Transmission cycles, host range, evolution and emergence of arboviral disease.

Genetic divergence and dispersal of yellow fever virus, Brazil.

Yellow fever virus infectivity for Bolivian Aedes aegypti mosquitoes.

Emergence of attenuated West Nile virus variants in Texas, 2003.

Characterization of a West Nile virus isolate from a human on the Gulf Coast of Texas.

An animal model for the tickborne flavivirus--Omsk hemorrhagic fever virus.

Genome sequence and attenuating mutations in West Nile virus isolate from Mexico.

Size heterogeneity in the 3' noncoding region of South American isolates of yellow fever virus.

Recombination and flavivirus vaccines: a commentary.

Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains.

Phenotypic and molecular characterization of a non-lethal, hamster-viscerotropic strain of yellow fever virus.

Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains.

Phylogenetic analysis of North American West Nile virus isolates, 2001-2004: evidence for the emergence of a dominant genotype.

West Nile Virus isolation in human and mosquitoes, Mexico.

Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil.

Introductions of West Nile virus strains to Mexico.

Genome analysis and phylogenetic relationships between east, central and west African isolates of Yellow fever virus.

A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice.

Structure of the envelope protein domain III of Omsk hemorrhagic fever virus.

A mutation in the envelope protein fusion loop attenuates mouse neuroinvasiveness of the NY99 strain of West Nile virus.

Yellow fever: a disease that has yet to be conquered.

NMR assignment of the dengue 4 virus envelope protein domain III.

Selection of thioaptamers for diagnostics and therapeutics.

Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections.

17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005.

A combination of naturally occurring mutations in North American West Nile virus nonstructural protein genes and in the 3' untranslated region alters virus phenotype.

Solution structure of the envelope protein domain III of dengue-4 virus.

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas.

Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.

Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.

Long range communication in the envelope protein domain III and its effect on the resistance of West Nile virus to antibody-mediated neutralization.

Flavivirus DNA vaccine with a kick.

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses.

Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

International laboratory network for yellow fever vaccine-associated adverse events.

The enigma of yellow fever in East Africa.

Genetic variation of St. Louis encephalitis virus.

Short report: comparison of oral infectious dose of West Nile virus isolates representing three distinct genotypes in Culex quinquefasciatus.

Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III.

Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

NMR assignments of the yellow fever virus envelope protein domain III.

NMR assignments of the sylvatic dengue 1 virus envelope protein domain III.

Genetic characterization of early isolates of Japanese encephalitis virus: genotype II has been circulating since at least 1951.

Structure of yellow fever virus envelope protein domain III.

Introduction to this supplement.

Development pathway for biodefense vaccines.

Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III.

Role of BC loop residues in structure, function and antigenicity of the West Nile virus envelope protein receptor-binding domain III.

Multiple pathways to the attenuation of West Nile virus in south-east Texas in 2003.

Comparative pathogenesis and systems biology for biodefense virus vaccine development.

Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape.

Genetic characterization of Japanese encephalitis virus genotype II strains isolated from 1951 to 1978.

Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas.

Evolution of new genotype of West Nile virus in North America.

The development of Dengue vaccines. Introduction.

Envelope and pre-membrane protein structural amino acid mutations mediate diminished avian growth and virulence of a Mexican West Nile virus isolate.

Flavivirus-induced antibody cross-reactivity.

Multiple amino acid changes at the first glycosylation motif in NS1 protein of West Nile virus are necessary for complete attenuation for mouse neuroinvasiveness.

Reduced avian virulence and viremia of West Nile virus isolates from Mexico and Texas.

Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes.

Mutational analysis of the West Nile virus NS4B protein.

Editorial commentary. Short-course oral corticosteroid therapy is not effective in early dengue infection.

Characterization of Epstein-Barr virus reactivation in a modeled spaceflight system.

The Molecular Evolution of Lineage 2 West Nile Virus.

Dynamic transmission of West Nile virus across the United States-Mexican border.

Vertebrate attenuated West Nile virus mutants have differing effects on vector competence in Culex tarsalis mosquitoes.

Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into east and west Africa.

Genetic diversity of Japanese encephalitis virus isolates obtained from the indonesian archipelago between 1974 and 1987.

Resurgence of West Nile neurologic disease in the United States in 2012: what happened? What needs to be done?

A West Nile virus NS4B-P38G mutant strain induces adaptive immunity via TLR7-MyD88-dependent and independent signaling pathways.

Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.

Continued evolution of West Nile virus, Houston, Texas, USA, 2002-2012.

Phylogeography of Japanese encephalitis virus: genotype is associated with climate.

Molecular epidemiology and evolution of West Nile virus in North America.

Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing.

Dynamics of the emergence and establishment of a newly dominant genotype of Japanese encephalitis virus throughout Asia.

Economic burden of West Nile virus in the United States.

Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.

Thermodynamic mechanism for the evasion of antibody neutralization in flaviviruses.

Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice.

Functional Analysis of DENV-2 Envelope Protein Domain 3 Type-Specific and DENV Complex-Reactive Critical Epitope Residues.

Evidence for Co-evolution of West Nile Virus and House Sparrows in North America.

A lethal murine infection model for dengue virus 3 in AG129 mice deficient in Type I and II interferon receptors leads to systemic disease.

Attenuated West Nile virus mutant NS1130-132QQA/175A/207A exhibits virus-induced ultrastructural changes and accumulation of protein in the Endoplasmic Reticulum.